Register | Log in | FAQ      [?] 

Nature Reviews Drug Discovery

Articles from the last few issues of Nature Reviews Drug Discovery © Nature Publishing Group
  • Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.
    Nature reviews. Drug discovery (10 October 2008)
    by Norberto Perico, Ariela Benigni, Giuseppe Remuzzi
    posted by 1 person jyuh
  • Neurodegenerative disease: New ways of tackling Aβ toxicity
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (17 October 2008), pp. 889-889.
    by Monica H Flight
  • Cardiovascular disease: Enhanced protection of the heart
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (17 October 2008), pp. 892-892.
    by Man T Tse
  • Antibacterial drugs: New paths to beating bacteria
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (17 October 2008), pp. 891-891.
    by Sarah Crunkhorn
  • Genomic-scale prioritization of drug targets: the TDR Targets database
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (17 October 2008), pp. 900-907.
    by Fernán Agüero, Bissan Al-Lazikani, Martin Aslett, Matthew Berriman, Frederick S Buckner, Robert K Campbell, Santiago Carmona, Ian M Carruthers, Edith AW Chan, Feng Chen, Gregory J Crowther, Maria A Doyle, Christiane Hertz-Fowler, Andrew L Hopkins, Gregg Mcallister, Solomon Nwaka, John P Overington, Arnab Pain, Gaia V Paolini, Ursula Pieper, Stuart A Ralph, Aaron Riechers, David S Roos, Andrej Sali, Dhanasekaran Shanmugam, Takashi Suzuki, Wesley C Van Voorhis, Christophe LMJ Verlinde
  • A decade of the Fast Track programme
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (24 October 2008), pp. 885-886.
    by Janice M Reichert, Stephanie L Rochon, Bodi D Zhang
    posted by 1 person reyez
  • Novel therapeutic applications of cardiac glycosides
    Nature Reviews Drug Discovery, Vol. 7, No. 11. (24 October 2008), pp. 926-935.
    by Ioannis Prassas, Eleftherios P Diamandis
  • Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 909-925.
    by Rocio S Lopez-Diego, Howard L Weiner
  • Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 893-899.
    by Christian K Schneider, Gabriele Schäffner-Dallmann
    posted by 1 person sg45653
  • Lung injury: Promoting fluid clearance
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 890-891.
    by Charlotte Harrison
  • Atherosclerosis: Preventing plaque rupture
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 890-891.
    by Alexandra Flemming
  • Romiplostim
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 887-888.
    by Douglas B Cines, Uma Yasothan, Peter Kirkpatrick
  • Pathways to cancer therapy
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 875-876.
    by Dan Jones
  • Payers growing influence on R&D decision making
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 876-878.
    by Bethan Hughes
  • Patent watch
    Nature Reviews Drug Discovery, Vol. 7, No. 11., pp. 882-883.
    by Charlotte Harrison
  • Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Nature Reviews Drug Discovery, Vol. 7, No. 10. (12 September 2008), pp. 818-826.
    by Hans-Georg Eichler, Francesco Pignatti, Bruno Flamion, Hubert Leufkens, Alasdair Breckenridge
  • Antipsychotics: Tuning muscarinic receptor signalling
    Nature Reviews Drug Discovery, Vol. 7, No. 10. (19 September 2008), pp. 806-806.
    by Monica H Flight
  • Immunomodulators: Two for the price of one?
    Nature Reviews Drug Discovery, Vol. 7, No. 10. (19 September 2008), pp. 804-805.
    by Man T Tse
  • Pharmacogenetics in drug discovery and development: a translational perspective
    Nature Reviews Drug Discovery, Vol. 7, No. 10. (19 September 2008), pp. 807-817.
    by Allen D Roses
  • Autoimmune Disease: Blocking the drivers
    Nature Reviews Drug Discovery, Vol. 7, No. 10. (19 September 2008), pp. 803-803.
    by Sarah Crunkhorn
    posted by 1 person reyez
  • The IL-33/ST2 pathway: therapeutic target and novel biomarker
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 827-840.
    by Rahul Kakkar, Richard T Lee
  • Hepatitis C therapies
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 799-800.
    by Irena Melnikova
  • Sirtuins — novel therapeutic targets to treat age-associated diseases
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 841-853.
    by Siva Lavu, Olivier Boss, Peter J Elliott, Philip D Lambert
    posted by 1 person jyuh
  • Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 854-868.
    by Aleksey G Kazantsev, Leslie M Thompson
    posted by 1 person sschurer
  • Anticancer Drugs: Partnering to promote apoptosis
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 805-805.
    by Charlotte Harrison
    posted by 1 person reyez
  • Immunotherapy: Cancer cells BiTE the dust
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 804-804.
    by Alexandra Flemming
    posted by 1 person reyez
  • Icatibant
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 801-802.
    by Konrad Bork, Uma Yasothan, Peter Kirkpatrick
    posted by 1 person reyez
  • Wellcome boost for open-access chemistry
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 789-790.
    by Sarah Houlton
  • New hope for Parkinson's disease progression delay
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 791-791.
    by Bethan Hughes
    posted by 1 person psique
  • Patent watch
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 796-797.
    by Charlotte Harrison
  • Market Watch: Pharma industry performance metrics: 2007–2012E
    Nature Reviews Drug Discovery, Vol. 7, No. 10., pp. 795-795.
    by Michael Goodman
  • Economic issues with follow-on protein products
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 733-737.
    by Michael Lanthier, Rachel Behrman, Clark Nardinelli
  • Informatics: New targets for old drugs
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 729-729.
    by Sarah Crunkhorn
    posted by 1 person reyez
  • Protein-Folding Diseases: Chaperones to the rescue
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 730-731.
    by Monica H Flight
  • Pharmacology: Flip to open
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 732-732.
    by Charlotte Harrison
  • Perspectives on NMR in drug discovery: a technique comes of age
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 738-745.
    by Maurizio Pellecchia, Ivano Bertini, David Cowburn, Claudio Dalvit, Ernest Giralt, Wolfgang Jahnke, Thomas L James, Steve W Homans, Horst Kessler, Claudio Luchinat, Bernd Meyer, Hartmut Oschkinat, Jeff Peng, Harald Schwalbe, Gregg Siegal
  • Nanoparticle therapeutics: an emerging treatment modality for cancer
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 771-782.
    by Mark E Davis, Zhuo ( Chen, Dong M Shin
  • Osteoporosis: overview and pipeline
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 725-726.
    by Uma Yasothan, Santwana Kar
  • Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 759-770.
    by György Haskó, Joel Linden, Bruce Cronstein, Pál Pacher
    posted by 1 person jyuh
  • Targeting of tetraspanin proteins — potential benefits and strategies
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 747-758.
    by Martin E Hemler
  • 60 years studying heart-disease risk
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 715-715.
    by Daniel Levy
  • Alvimopan
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 727-728.
    by Conor P Delaney, Uma Yasothan, Peter Kirkpatrick
  • Aanticancer Drugs: Proteasome inhibitor unleashes three-pronged attack
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 730-731.
    by Alexandra Flemming
  • Anticancer drugs: Autophagy targeted in kidney cancer
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 731-731.
    by Bethan Hughes
  • Mixed results for disease-modification strategies for Alzheimer's disease
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 717-718.
    by Alisa Opar
    posted by 1 person psique
  • Industry concern over EU hepatotoxicity guidance
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 719-719.
    by Bethan Hughes
  • Patent Watch
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 722-723.
    by Charlotte Harrison
  • Downsides to the nitrate–nitrite–nitric oxide pathway in physiology and therapeutics?
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 710-710.
    by Nirmal S Panesar
  • Downsides to the nitrate–nitrite–nitric oxide pathway in physiology and therapeutics? Reply from Lundberg, Weitzberg and Gladwin
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 710-710.
    by Jon O Lundberg, Eddie Weitzberg, Mark T Gladwin
  • The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 694-710.
    by David G Lambert
  • Note: You may cite this page as: http://www.citeulike.org/journal/nature-reviews-drug-discovery

    Result page: 1 2 3 4 5 6 7 8 9 10 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.